Anguilla vs New Caledonia: Tuberculosis patients living with HIV receiving antiretroviral therapy
Anguilla
0 patients
in 2016
New Caledonia
0 patients
in 2021
Anguilla rank
141st
New Caledonia rank
141st
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Anguilla
- New Caledonia
How they compare
Anguilla currently reports 0 patients against 0 patients in New Caledonia, a difference of 0 patients.
Across all 5 years both countries report, New Caledonia has been ahead every year.
Anguilla ranks 141st and New Caledonia ranks 141st of 183 countries.
Head to head by decade
| Decade | Anguilla | New Caledonia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0 patients | 0 patients | 0 patients | — |
| 2010s | 0 patients | 0 patients | 0 patients | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Anguilla or New Caledonia?
- Anguilla, at 0 patients against 0 patients in New Caledonia as of 2016.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Anguilla and New Caledonia?
- 0 patients, with Anguilla ahead.
- How many years of comparable data are there for Anguilla and New Caledonia?
- 5 years are reported by both, from 2003 to 2010.
- How do Anguilla and New Caledonia rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Anguilla ranks 141st and New Caledonia ranks 141st of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.